Researchers have identified key markers to help physicians predict whether or not a patient may respond positively to a type of melanoma therapy, according to a study published by Nature Communications in September.
Melanoma, a highly aggressive form of skin cancer, and the most deadly, accounts for around 60 percent of skin cancer deaths, according to the American Cancer Society.
Immune checkpoint inhibitor (ICI) therapy is currently the most efficient treatment for those with metastatic melanoma—which spreads cancer cells from the primary tumor to other areas of the body—demonstrating durable remission in up to half of patients with advanced melanoma. The therapy works by blocking proteins on tumor or immune cells that prevent the immune system from killing cancer cells….